Search
News & Events
New recommendations to stop antibiotics soonerThe Kids researchers are amongst a group of experts who have recommended that doctors can stop intravenous antibiotics sooner in children.
News & Events
Gastro gap between Aboriginal and non-Aboriginal children shrinkingThe world's largest study of gastroenteritis trends in children has shown the disparity between Aboriginal and non-Aboriginal health may be improving.
Research
Sore throat: Is it such a big deal anymore?This review article addresses the driving factors associated with diagnosis and treatment of sore throats caused by Group A streptococcus.
Research
Working towards a Group A Streptococcal vaccine: Report of a collaborative Trans-Tasman workshopThis paper is a report on progress towards a joint Australian and New Zealand vaccination program for Group A Streptococcus bacteria, which causes serious...
Research
Assessing the effect of meningitis prevention and treatment.In high-income countries serious bacterial infections such as meningitis are uncommon, but their severity has led to prompt adoption of vaccines for...
Research
Predictors of Disease Severity in Children Hospitalized for Pertussis during an EpidemicThis study aimed to determine factors associated with severe pertussis in hospitalized children during an epidemic using a novel pertussis severity scoring...
Research
Characterization of G2P[4] rotavirus strains causing outbreaks of gastroenteritis in the Northern Territory, Australia, in 1999, 2004 and 2009Outbreaks of rotavirus diarrhea cause a large disease burden in the Alice Springs region of the Northern Territory, Australia.
Research
Invasive Staphylococcus aureus Infections in Children in Tropical Northern AustraliaWe conducted a retrospective review for all cases of S aureus bacteremia and sterile site infections, for children under 15 years, in northern Australia over...
Research
Clinical Management of Staphylococcus aureus Bacteremia in Neonates, Children, and AdolescentsStaphylococcus aureus is a common cause of community and health care-associated bacteremia, with authors of recent studies estimating the incidence of S aureus bacteremia (SAB) in high-income countries between 8 and 26 per 100 000 children per year. Despite this, <300 children worldwide have ever been randomly assigned into clinical trials to assess the efficacy of treatment of SAB.
Research
Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season.